TSTickerStarGet alerts

Alumis Reports Q3 2026 Financial Results; LUMUS Phase 2b Trial in SLE Missed Primary Endpoint in Overall Population

Alumis reported Q3 2026 net loss of $94.9 million versus net loss of $110.8 million in Q3 2025, as R&D expenses declined to $80.8 million from $97.8 million. Revenue was $1.9 million, down slightly from $2.1 million in the prior-year quarter. The Phase 2b LUMUS trial for envudeucitinib in systemic lupus erythematosus (SLE) did not meet primary or secondary endpoints in the overall trial population, though robust clinical responses were observed in a prespecified subgroup of patients with high interferon gene sig...

Share this story

Forward guidance

Cash runwayQ4 2027
Q4 2027

Key takeaways

  • Net loss narrowed to $94.9 million in Q3 2026 from $110.8 million in Q3 2025, driven by lower R&D spending as the pivotal Phase 3 ONWARD1 and ONWARD2 trials completed.

  • Revenue declined to $1.9 million from $2.1 million, reflecting collaboration revenue from the Kaken Pharmaceutical agreement.

  • LUMUS Phase 2b trial in SLE missed primary endpoint in overall population but showed positive results in IFNGS-high subgroup, which represents the majority of moderate-to-severe SLE cases.

  • Cash, cash equivalents and marketable securities totaled $431.3 million as of September 30, 2026, sufficient to fund operations into Q4 2027.

  • Company remains on track to submit NDA for envudeucitinib in moderate-to-severe plaque psoriasis in Q4 2026.

  • Phase 2 two-year safety data for envudeucitinib expected in Q4 2026.

Key metrics

Net lossQ3 2026
$94.9 millionimproved from $110.8 million net loss
Total revenueQ3 2026
$1.9 milliondown from $2.1 million
Collaboration revenueQ3 2026
$1.9 milliondown from $2.1 million
Research and development expensesQ3 2026
$80.8 milliondown from $97.8 million
General and administrative expensesQ3 2026
$20.2 millionup from $19.5 million
Cash, cash equivalents and marketable securitiesQ3 2026
$431.3 million

Disclosure changes

  • Clinical trial results

    Phase 2b LUMUS trial of envudeucitinib for SLE did not meet primary and secondary endpoints in the overall trial population; robust clinical responses observed in prespecified IFNGS-high subgroup including on BICLA, CLASI-50, SRI-4, and LLDAS endpoints.

    LUMUS missed overall population endpoints but IFNGS-high subgroup showed positive results; IFNGS-high patients represent majority of moderate-to-severe SLE cases but were under-represented in trial
  • Intangible assets impairment

    Nine months ended September 30, 2026 includes $41.8 million intangible assets impairment loss; no impairment in Q3 2026

    Material impairment charge of $41.8 million recorded in nine months 2026 related to intangible assets

Primary source

TickerStar generated this brief from an official company, investor-relations, earnings-call, or regulatory source. Review the primary material before making an investment decision.

Open SEC filing

Follow ALMS in real time

Get material earnings, filing, IR, and earnings-call alerts by email.

Create a free alert